Last week, Quartz Bio said that it had been selected to provide bioinformatics support for biomarker projects conducted by the Debiopharm group, a Swiss-based biopharmaceutical company.
Under the terms of the one-year agreement, the Merck Serono spinoff (BI 9/7/2012) will provide computational analyses for Debiopharm projects in areas such as preclinical next-generation sequencing and clinical biomarker data analyses.
The financial details of the deal are not being disclosed.